Nintedanib Teva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—vascular endothelial growth factor receptor (VEGFR), platelet‑derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). By inhibiting these signals, it reduces fibroblast activation, extracellular matrix deposition, and abnormal blood‑vessel formation, which are central to fibrotic lung disease and tumor growth.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and concomitant therapies. Healthcare professionals follow the approved prescribing information and adjust the regimen as needed for safety and efficacy.

Safety data for Nintedanib in pregnant or lactating women are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, another anti‑fibrotic agent. While both slow disease progression, Nintedanib targets a broader range of tyrosine kinases, which may offer additional benefit in certain patients, especially those with combined vascular involvement. Choice of therapy depends on efficacy, tolerability, drug‑interaction profile and physician judgment.

Nintedanib tablets should be stored at room temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Nintedanib is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not alter the schedule without medical advice.

Serious adverse events include severe liver injury, significant bleeding, cardiovascular complications such as myocardial infarction or stroke, and rare cases of gastrointestinal perforation. Patients should be monitored regularly for liver enzyme elevations, signs of bleeding, and cardiovascular symptoms.

Nintedanib is contraindicated in patients with severe hepatic impairment, active uncontrolled bleeding, or known hypersensitivity to the drug. Caution is also advised for individuals with recent major cardiovascular events, uncontrolled hypertension, or those taking strong CYP3A4 inhibitors.